Veraxa Biotech names Raju Willener as new CFO
The Zurich-based cancer therapy developer announced the leadership change effective September 4, 2026, in a filing that also details Willener's prior finance roles.
SEC filing
Latest
2 stories
Friday, September 4
Monday, August 10
Veraxa Biotech completes SPAC merger, registers resale of over 145 million shares
Two prospectuses filed August 10, 2026 cover warrant exercise shares, insider resale shares, and a $50 million Lincoln Park equity line following the company's Nasdaq debut.
SEC filing (2)